Rothschild Investment LLC Sells 1,272 Shares of Novo Nordisk A/S (NYSE:NVO)

Rothschild Investment LLC decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 120,840 shares of the company’s stock after selling 1,272 shares during the period. Rothschild Investment LLC’s holdings in Novo Nordisk A/S were worth $8,391,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Victory Capital Management Inc. grew its position in Novo Nordisk A/S by 58.5% in the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock valued at $5,410,000 after acquiring an additional 23,223 shares during the last quarter. Bryn Mawr Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 358.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after purchasing an additional 30,420 shares during the last quarter. Clear Creek Financial Management LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $450,000. DSM Capital Partners LLC grew its holdings in shares of Novo Nordisk A/S by 16.7% during the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock valued at $172,678,000 after purchasing an additional 286,912 shares during the last quarter. Finally, Channing Global Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $354,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $71.40 on Friday. The business’s 50 day simple moving average is $65.58 and its 200 day simple moving average is $81.77. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The stock has a market capitalization of $320.41 billion, a PE ratio of 21.70, a PEG ratio of 0.90 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion for the quarter. As a group, research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NVO. Guggenheim cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. BMO Capital Markets restated a “market perform” rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. BNP Paribas started coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an “underperform” rating on the stock. Finally, Wall Street Zen upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $128.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.